KYMR

SEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,522

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.235 to $35.195. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-011747 · doc4.xml · derivative · entry 6

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,061

Underlying: Common Stock · 8,195 shares

Expires 2030-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date

SEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 4

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.675. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 3

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,195

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-011749 · doc4.xml · derivative · entry 6

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,007

Underlying: Common Stock · 7,800 shares

Expires 2028-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 4

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,547

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 3

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-021145 · doc4.xml · nonDerivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · shares: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") for no additional consideration to its limited partners and its general partner, Atlas Venture Associates X, L.P. ("AVA X LP"), subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.

F2 · ownership.nature: These shares are held directly by AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-021139 · doc4.xml · nonDerivative · entry 1

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") for no additional consideration to its limited partners and its and general partner, Atlas Venture Associates X, L.P. ("AVA X LP"), subsequent to the Reporting Persons' last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Persons' ownership in such shares, the Reporting Persons were not required to report the distribution pursuant to Section 16.

F2 · ownership.direct: The shares are held directly by AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-21-011985 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2031-03-11

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021.

SEC source: 0000899243-22-014878 · doc4a.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,919

Underlying: Common Stock · 20,919 shares

Expires 2031-03-11

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021.

SEC source: 0000899243-21-011747 · doc4.xml · derivative · entry 5

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,256

Underlying: Common Stock · 1,805 shares

Expires 2030-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date

SEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-011747 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-011749 · doc4.xml · derivative · entry 5

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,807

Underlying: Common Stock · 2,200 shares

Expires 2028-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 2

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,052

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,747

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-010463 · doc4.xml · derivative · entry 5

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,061

Underlying: Common Stock · 10,000 shares

Expires 2030-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 4

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 3

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,301

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-010463 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-010156 · doc4.xml · derivative · entry 5

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,061

Underlying: Common Stock · 20,000 shares

Expires 2030-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 4

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.60 to $46.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 3

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.60 to $45.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,119

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.56 to $44.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-010156 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-009410 · doc4.xml · derivative · entry 1

Chesworth Richard · CIK 0001821188 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2031-02-28

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.

SEC source: 0000899243-21-009412 · doc4.xml · derivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,000

Underlying: Common Stock · 375,000 shares

Expires 2031-02-28

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.

SEC source: 0000899243-21-009416 · doc4.xml · derivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-02-28

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.

SEC source: 0000899243-21-009388 · doc4.xml · derivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2031-02-28

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.

SEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 3

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,547

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 2

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,222

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,507

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 3

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,611

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 2

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,498

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0001209191-21-012760 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,885,631

F1 · kind: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on November 17, 2020.

SEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,997

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0000899243-20-024765 · doc4.xml · derivative · entry 1

Esposito Pamela · CIK 0001744425 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-09-03

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on September 4, 2020.

SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · derivative · entry 3

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 154,432 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · derivative · entry 2

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 313,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001722024-20-000012 · wf-form4_159839496225044.xml · nonDerivative · entry 1

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 1.5949 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on August 25, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001104659-20-098390 · tm2029366d1_4.xml · derivative · entry 2

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,630,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-0.626998558 basis and had no expiration date.

F1 · derivative.exercise_date: The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-0.626998558 basis and had no expiration date.

F1 · derivative.expiration_date: The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-0.626998558 basis and had no expiration date.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-098390 · tm2029366d1_4.xml · nonDerivative · entry 1

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,630,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series C Convertible Preferred Stock converted into shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-0.626998558 basis and had no expiration date.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000899243-20-023369 · doc4.xml · derivative · entry 3

Hall Steven Edward · CIK 0001602732 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 617,732 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

SEC source: 0000899243-20-023369 · doc4.xml · derivative · entry 2

Hall Steven Edward · CIK 0001602732 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,574,517 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

SEC source: 0000899243-20-023369 · doc4.xml · nonDerivative · entry 1

Hall Steven Edward · CIK 0001602732 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,192,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

SEC source: 0000899243-20-023368 · doc4.xml · derivative · entry 6

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,112,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Dr. Booth is a member of AVAO LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023368 · doc4.xml · derivative · entry 5

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 926,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.